VX17-659-105: A Phase 3, Open-label Study Evaluating the

Project: Research project

Project Details

Description

VX17-659-105: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
StatusActive
Effective start/end date5/9/185/1/21

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.